News
UBS upgraded Alkermes (NASDAQ:ALKS) to Buy from Neutral on Tuesday, citing prospects for Irish biotech’s orexin 2 receptor ...
Analysts have recently evaluated Alkermes and provided 12-month price targets. The average target is $42.17, accompanied by a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback